Clinical Trial Update: Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating bone marrow–derived mesenchymal stem cell therapy for severe COVID-19.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Disease 2019

Drugs mentioned

• Bone marrow-derived mesenchymal stem cells (bone marrow-derived mesenchymal stem cells)

Snippet

Sponsor: Guangzhou Institute of Respiratory Disease | Conditions: Coronavirus Disease 2019 (COVID-19) | Phase 1, Phase 2 | Status: UNKNOWN